Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study.

Administering additional intravitreal topotecan injections (plus two) following the complete regression of vitreous seeds may contribute to reducing the recurrence rate in patients with retinoblastoma.

This approach enhances the long-term efficacy of intravitreal injections, thereby contributing to higher eye salvage rates. However, the retrospective, non-randomised design and small sample size remain limitations.

Multicentre prospective studies are warranted to validate these findings and refine treatment protocols.